Regencell Bioscience Holdings (RGC) Equity Ratio (2020 - 2025)

Regencell Bioscience Holdings (RGC) reported Equity Ratio of 0.4 for Q4 2025, down 52.08% quarter-over-quarter from 0.84 in Q2 2025.

Regencell Bioscience Holdings (RGC) Equity Ratio (2020 - 2025) Analysis & Trends

Regencell Bioscience Holdings has reported Equity Ratio for 3 years, with the latest figure at 0.4 in Q4 2025.

For the quarter ending Q4 2025, Equity Ratio changed N/A year-over-year to 0.4; the trailing twelve-month figure through Dec 2025 stood at 0.14 (changed N/A YoY), and the FY2025 full-year result was 0.84, changed N/A from the prior year.
Equity Ratio for Q4 2025 stood at 0.4, down from 0.84 in the prior quarter.
The five-year high for Equity Ratio was 0.95 in Q2 2023, with the low at 0.4 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Ratio (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	0.21
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	0.21
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	0.88
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	0.73
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	0.69
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	0.49
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	0.41
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	0.20
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	0.52
10	Regencell Bioscience Holdings	-	-	-	0.40

Download Data